Literature DB >> 24448737

Therapy for patients with antibodies to complement factor H associated HUS.

Arvind Bagga1, Aditi Sinha, Marie-Agnes Dragon-Durey.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24448737     DOI： 10.1007/s00467-013-2729-8

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN： 0931-041X            Impact factor:   3.714


× No keyword cloud information.
  3 in total

1.  Complement factor H-related protein 1 deficiency and factor H antibodies in pediatric patients with atypical hemolytic uremic syndrome.

Authors:  Johannes Hofer; Andreas R Janecke; L B Zimmerhackl; Magdalena Riedl; Alejandra Rosales; Thomas Giner; Gerard Cortina; Carola J Haindl; Barbara Petzelberger; Miriam Pawlik; Verena Jeller; Udo Vester; Bettina Gadner; Michael van Husen; Michael L Moritz; Reinhard Würzner; Therese Jungraithmayr
Journal:  Clin J Am Soc Nephrol       Date:  2012-12-14       Impact factor: 8.237

2.  Prompt plasma exchanges and immunosuppressive treatment improves the outcomes of anti-factor H autoantibody-associated hemolytic uremic syndrome in children.

Authors:  Aditi Sinha; Ashima Gulati; Savita Saini; Caroline Blanc; Aarti Gupta; Bahadur Singh Gurjar; Himanshi Saini; Shambhuprasad T Kotresh; Uma Ali; Divya Bhatia; Alpana Ohri; Manish Kumar; Indira Agarwal; Sanjeev Gulati; Kanav Anand; M Vijayakumar; Rajiv Sinha; Sidharth Sethi; Maud Salmona; Anna George; Vineeta Bal; Geetika Singh; Amit K Dinda; Pankaj Hari; Satyajit Rath; Marie-Agnes Dragon-Durey; Arvind Bagga
Journal:  Kidney Int       Date:  2013-10-02       Impact factor: 10.612

3.  Successful treatment of DEAP-HUS with eculizumab.

Authors:  Damien Noone; Aoife Waters; Fred G Pluthero; Denis F Geary; Michael Kirschfink; Peter F Zipfel; Christoph Licht
Journal:  Pediatr Nephrol       Date:  2013-11-20       Impact factor: 3.714
  3 in total
  1 in total

1.  Treatment of DEAP-HUS--seeking the best strategy.

Authors:  Christoph Licht; Damien Noone
Journal:  Pediatr Nephrol       Date:  2014-02-15       Impact factor: 3.714
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.